These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 20087842)

  • 41. Multilevel modelling of clustered grouped survival data using Cox regression model: an application to ART dental restorations.
    Wong MC; Lam KF; Lo EC
    Stat Med; 2006 Feb; 25(3):447-57. PubMed ID: 16143989
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Imputation of missing variance data using non-linear mixed effects modelling to enable an inverse variance weighted meta-analysis of summary-level longitudinal data: a case study.
    Boucher M
    Pharm Stat; 2012; 11(4):318-24. PubMed ID: 22566382
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of data analysis strategies for intent-to-treat analysis in pre-test-post-test designs with substantial dropout rates.
    Salim A; Mackinnon A; Christensen H; Griffiths K
    Psychiatry Res; 2008 Sep; 160(3):335-45. PubMed ID: 18718673
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Bayesian fixed effects analysis of the Mantel-Haenszel model applied to meta-analysis.
    Leonard T; Duffy JC
    Stat Med; 2002 Aug; 21(16):2295-312. PubMed ID: 12210615
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Estimating equations with incomplete categorical covariates in the Cox model.
    Lipsitz SR; Ibrahim JG
    Biometrics; 1998 Sep; 54(3):1002-13. PubMed ID: 9750248
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of latent construct correlations in the presence of missing data: a note on a latent variable modelling approach.
    Raykov T
    Br J Math Stat Psychol; 2012 Feb; 65(1):19-31. PubMed ID: 22233174
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bayesian sensitivity models for missing covariates in the analysis of survival data.
    Hemming K; Hutton JL
    J Eval Clin Pract; 2012 Apr; 18(2):238-46. PubMed ID: 21114712
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Incorporating data from various trial designs into a mixed treatment comparison model.
    Schmitz S; Adams R; Walsh C
    Stat Med; 2013 Jul; 32(17):2935-49. PubMed ID: 23440610
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Empirical Likelihood in Nonignorable Covariate-Missing Data Problems.
    Xie Y; Zhang B
    Int J Biostat; 2017 Apr; 13(1):. PubMed ID: 28441139
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Imputation method adjusted for covariates for nonrespondents in instruments with applications.
    Li J; Chi EM; Feng C; Chow SC
    J Biopharm Stat; 2011 Mar; 21(2):342-54. PubMed ID: 21391006
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Multivariate meta-analysis: a robust approach based on the theory of U-statistic.
    Ma Y; Mazumdar M
    Stat Med; 2011 Oct; 30(24):2911-29. PubMed ID: 21830230
    [TBL] [Abstract][Full Text] [Related]  

  • 52. On Gaussian Markov random fields and Bayesian disease mapping.
    MacNab YC
    Stat Methods Med Res; 2011 Feb; 20(1):49-68. PubMed ID: 20547586
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Meta-analysis of a continuous outcome combining individual patient data and aggregate data: a method based on simulated individual patient data.
    Yamaguchi Y; Sakamoto W; Goto M; Staessen JA; Wang J; Gueyffier F; Riley RD
    Res Synth Methods; 2014 Dec; 5(4):322-51. PubMed ID: 26052956
    [TBL] [Abstract][Full Text] [Related]  

  • 54. On the utility of the Dirichlet distribution for meta-analysis of clinical studies.
    Sankoh AJ; Al-Osh M; Huque MF
    J Biopharm Stat; 1999 May; 9(2):289-306. PubMed ID: 10379695
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Statistical approaches for conducting network meta-analysis in drug development.
    Jones B; Roger J; Lane PW; Lawton A; Fletcher C; Cappelleri JC; Tate H; Moneuse P;
    Pharm Stat; 2011; 10(6):523-31. PubMed ID: 22213533
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Direct likelihood inference and sensitivity analysis for competing risks regression with missing causes of failure.
    Moreno-Betancur M; Rey G; Latouche A
    Biometrics; 2015 Jun; 71(2):498-507. PubMed ID: 25761785
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A comparison of the results of intent-to-treat, per-protocol, and g-estimation in the presence of non-random treatment changes in a time-to-event non-inferiority trial.
    Matsuyama Y
    Stat Med; 2010 Sep; 29(20):2107-16. PubMed ID: 20552682
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Higher-order likelihood inference in meta-analysis and meta-regression.
    Guolo A
    Stat Med; 2012 Feb; 31(4):313-27. PubMed ID: 22173666
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Testing overall and moderator effects in random effects meta-regression.
    Huizenga HM; Visser I; Dolan CV
    Br J Math Stat Psychol; 2011 Feb; 64(Pt 1):1-19. PubMed ID: 21506942
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Methods for the joint meta-analysis of multiple tests.
    Trikalinos TA; Hoaglin DC; Small KM; Terrin N; Schmid CH
    Res Synth Methods; 2014 Dec; 5(4):294-312. PubMed ID: 26052954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.